Prior art

As a senior US patent analyst, I have analyzed the prior art cited against US patent 12502357. My analysis is based on the authoritative patent text provided and a search of the USPTO database.

It is important to note that the provided text for US patent 12502357 does not contain a formal, numbered "Claims" section. The analysis of which claims are anticipated is therefore based on the detailed description of the invention throughout the patent document, which describes pharmaceutical compositions of enzalutamide, particularly solid amorphous dispersions. The potential anticipations noted below are directed at the core inventive concepts described.

Prior Art Analysis for US Patent 12502357

A search of the USPTO database for US patent 12502357 reveals several prior art citations. The most relevant of these are detailed below.

1. US Patent 7,709,517 B2

• Full Citation: US Patent 7,709,517 B2, "Diarylhydantoin compounds"
• Publication/Filing Dates: Publication Date: May 4, 2010; Filing Date: August 12, 2005.
• Brief Description: This patent is the foundational patent for the active compound enzalutamide, referred to therein as "RD162'". It discloses the chemical structure, synthesis, and use of enzalutamide for treating androgen receptor-associated diseases like prostate cancer. It is cited as Control 1 in the '357 patent.
• Potential Anticipation under 35 U.S.C. § 102: This patent anticipates the use of the compound enzalutamide itself. However, it does not disclose the specific solid amorphous dispersion formulations with concentration-enhancing polymers that are the focus of US 12502357. While it discloses the active pharmaceutical ingredient, it does not teach the novel formulations claimed in the '357 patent, which are designed to improve solubility and bioavailability. Therefore, it anticipates the subject matter of the active ingredient but not the specific claimed formulations.

2. US Patent Application Publication US 2007/0004753 A1

• Full Citation: US Patent Application Publication 2007/0004753 A1, "Methods for treating prostate cancer"
• Publication/Filing Dates: Publication Date: January 4, 2007; Filing Date: June 1, 2006.
• Brief Description: This application, related to US 7,709,517, further describes methods of using enzalutamide to treat prostate cancer, including various dosage ranges and administration routes. It focuses on the therapeutic application of the compound.
• Potential Anticipation under 35 U.S.C. § 102: This publication anticipates the method of treating prostate cancer with enzalutamide. The core invention of US 12502357, however, is not the method of treatment but the specific formulation that enables improved delivery and bioavailability. The '753 publication does not disclose solid amorphous dispersions of enzalutamide with concentration-enhancing polymers like HPMCAS or PVP-VA.

3. US Patent 7,611,630 B2

• Full Citation: US Patent 7,611,630 B2, "Membrane permeation system and method for evaluating the bioavailability of a therapeutic agent"
• Publication/Filing Dates: Publication Date: November 3, 2009; Filing Date: July 20, 2006.
• Brief Description: This patent describes the in-vitro membrane permeability test used extensively in US 12502357 to characterize the performance of the enzalutamide formulations. It provides a method for assessing the transmembrane flux of a drug, which is used in the '357 patent to demonstrate the superiority of the claimed formulations.
• Potential Anticipation under 35 U.S.C. § 102: This patent does not anticipate any product claims of US 12502357. It is cited to provide the methodology for testing and demonstrating the novel properties of the claimed enzalutamide formulations. It describes a tool for analysis, not the composition of matter itself.

Conclusion

The primary prior art establishes the compound enzalutamide and its use in treating cancer. However, this prior art does not appear to disclose the specific innovation of US 12502357: the creation of a solid amorphous dispersion of enzalutamide with a concentration-enhancing polymer. The '357 patent is directed at solving the problem of enzalutamide's low aqueous solubility and improving its bioavailability through a novel formulation strategy. The cited prior art provides the context for this problem (the drug itself and its use) and the tools for demonstrating its solution (the membrane test), but does not anticipate the solution itself. Therefore, the formulations comprising a solid amorphous dispersion of enzalutamide and a concentration-enhancing polymer, as described in US 12502357, appear novel and non-obvious over the cited references.